North American Management Corp held its position in shares of Pfizer, Inc. (NYSE:PFE) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 39,431 shares of the biopharmaceutical company’s stock at the end of the second quarter. North American Management Corp’s holdings in Pfizer were worth $1,324,000 as of its most recent SEC filing.
Other institutional investors have also made changes to their positions in the company. Norges Bank acquired a new position in shares of Pfizer during the fourth quarter valued at $1,896,890,000. Asset Management One Co. Ltd. raised its position in shares of Pfizer by 618.4% in the fourth quarter. Asset Management One Co. Ltd. now owns 11,094,592 shares of the biopharmaceutical company’s stock valued at $360,362,000 after buying an additional 9,550,335 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main acquired a new position in shares of Pfizer during the fourth quarter valued at $289,666,000. Appaloosa LP acquired a new position in shares of Pfizer during the fourth quarter valued at $156,229,000. Finally, I.G. Investment Management LTD. raised its position in shares of Pfizer by 24.7% in the fourth quarter. I.G. Investment Management LTD. now owns 11,087,884 shares of the biopharmaceutical company’s stock valued at $360,134,000 after buying an additional 2,194,738 shares in the last quarter. Institutional investors and hedge funds own 69.94% of the company’s stock.
Pfizer, Inc. (NYSE:PFE) traded down 0.85% on Friday, reaching $32.67. 15,490,145 shares of the company were exchanged. The stock has a market capitalization of $194.30 billion, a P/E ratio of 23.90 and a beta of 1.00. The company’s 50-day moving average price is $33.30 and its 200-day moving average price is $33.38. Pfizer, Inc. has a 12-month low of $29.83 and a 12-month high of $35.38.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The firm had revenue of $12.90 billion for the quarter, compared to the consensus estimate of $13.08 billion. During the same quarter in the prior year, the company posted $0.64 earnings per share. The business’s revenue was down 1.9% on a year-over-year basis. Equities research analysts anticipate that Pfizer, Inc. will post $2.56 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Friday, August 4th will be issued a dividend of $0.32 per share. The ex-dividend date of this dividend is Wednesday, August 2nd. This represents a $1.28 annualized dividend and a yield of 3.92%. Pfizer’s payout ratio is 94.12%.
ILLEGAL ACTIVITY NOTICE: “Pfizer, Inc. (PFE) Stake Held by North American Management Corp” was originally posted by BNB Daily and is the property of of BNB Daily. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://www.baseball-news-blog.com/2017/08/19/pfizer-inc-pfe-position-held-by-north-american-management-corp-updated-updated-updated.html.
PFE has been the topic of several analyst reports. Citigroup Inc. lowered shares of Pfizer from a “neutral” rating to a “sell” rating and cut their price objective for the company from $38.00 to $31.00 in a report on Tuesday, May 16th. Credit Suisse Group lowered shares of Pfizer from an “outperform” rating to a “neutral” rating and cut their price objective for the company from $38.00 to $36.00 in a report on Thursday, July 20th. Zacks Investment Research upgraded shares of Pfizer from a “sell” rating to a “hold” rating in a report on Friday, July 14th. Barclays PLC reiterated a “buy” rating and issued a $38.00 target price on shares of Pfizer in a report on Wednesday, May 3rd. Finally, Sanford C. Bernstein reiterated a “buy” rating and issued a $37.00 target price on shares of Pfizer in a report on Wednesday, May 3rd. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have given a buy rating to the stock. Pfizer presently has a consensus rating of “Hold” and an average target price of $37.61.
In other news, insider Alexander R. Mackenzie sold 15,000 shares of the company’s stock in a transaction on Monday, August 7th. The shares were sold at an average price of $33.50, for a total value of $502,500.00. Following the completion of the sale, the insider now owns 151,474 shares in the company, valued at approximately $5,074,379. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Ian C. Read sold 96,950 shares of the company’s stock in a transaction on Friday, August 4th. The stock was sold at an average price of $34.00, for a total transaction of $3,296,300.00. The disclosure for this sale can be found here. Corporate insiders own 0.06% of the company’s stock.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.